<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">631988</article-id><article-id pub-id-type="doi">10.26442/00403660.2024.05.202705</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Bone mineral density in women with rheumatoid arthritis: A link between immune and biochemical markers</article-title><trans-title-group xml:lang="ru"><trans-title>Минеральная плотность костной ткани у женщин с ревматоидным артритом: связь с иммунологическими и биохимическими маркерами</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2809-0197</contrib-id><contrib-id contrib-id-type="scopus">57197823569</contrib-id><name-alternatives><name xml:lang="en"><surname>Dobrovolskaya</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Добровольская</surname><given-names>Ольга Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>кандидат мед. наук, науч. сотрудник лаб. остеопороза</p></bio><email>olgavdobr@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0961-9785</contrib-id><contrib-id contrib-id-type="scopus">7006802179</contrib-id><name-alternatives><name xml:lang="en"><surname>Demin</surname><given-names>Nikolay V.</given-names></name><name xml:lang="ru"><surname>Демин</surname><given-names>Николай Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>младший научный сотрудник лаб. остеопороза</p></bio><email>deminick@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0560-3495</contrib-id><name-alternatives><name xml:lang="en"><surname>Kozyreva</surname><given-names>Maria V.</given-names></name><name xml:lang="ru"><surname>Козырева</surname><given-names>Мария Витальевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>младший научный сотрудник лаб. остеопороза</p></bio><email>doginya@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7501-9185</contrib-id><name-alternatives><name xml:lang="en"><surname>Samarkina</surname><given-names>Elena Yu.</given-names></name><name xml:lang="ru"><surname>Самаркина</surname><given-names>Елена Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>младший научный сотрудник лаб. иммунологии и молекулярной биологии ревматических заболеваний</p></bio><email>samarkinale@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6404-0042</contrib-id><contrib-id contrib-id-type="scopus">8960133600</contrib-id><name-alternatives><name xml:lang="en"><surname>Diatroptov</surname><given-names>Michail E.</given-names></name><name xml:lang="ru"><surname>Диатроптов</surname><given-names>Михаил Евгеньевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор биол. наук, ст. науч. сотр. лаб. иммунологии и молекулярной биологии ревматических заболеваний</p></bio><email>diatrom@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4739-4302</contrib-id><contrib-id contrib-id-type="scopus">6507457856</contrib-id><name-alternatives><name xml:lang="en"><surname>Toroptsova</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Торопцова</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор мед. наук, зав. лаб. остеопороза</p></bio><email>torop@irramn.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Nasonova Research Institute of Rheumatology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-06-03" publication-format="electronic"><day>03</day><month>06</month><year>2024</year></pub-date><volume>96</volume><issue>5</issue><issue-title xml:lang="en">Issues of rheumatology</issue-title><issue-title xml:lang="ru">Вопросы ревматологии</issue-title><fpage>494</fpage><lpage>499</lpage><history><date date-type="received" iso-8601-date="2024-05-14"><day>14</day><month>05</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-05-15"><day>15</day><month>05</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/631988">https://ter-arkhiv.ru/0040-3660/article/view/631988</self-uri><abstract xml:lang="en"><p><bold>Aim</bold><bold>. </bold>To study the association of bone mineral density (BMD) with serum biochemical and immunological markers in postmenopausal women with rheumatoid arthritis (RA).</p> <p><bold>Materials</bold><bold> </bold><bold>and</bold><bold> </bold><bold>methods</bold><bold>. </bold>The study included 173 women with RA (age 61.0 [56.0; 66.0] years). A survey, dual-energy X-ray absorptiometry to measure the BMD of the lumbar spine (L<sub>I</sub>–L<sub>IV</sub>), femoral neck (FN) and total hip (TH), routine blood chemistry, measurement of C-reactive protein (CRP), rheumatoid factor, cyclic citrullinated peptide antibodies (CCPA), parathyroid hormone (PTH), vitamin D<sub>3</sub>, myostatin, follistatin, interleukin-6 (IL-6), IL-6 receptors, insulin-like growth factor 1, adiponectin, leptin, fibroblast growth factor 23, and tumor necrosis factor SF12 were performed.</p> <p><bold>Results</bold><bold>. </bold>PTH (β=-0.22, -0.35 and -0.30 for L<sub>I</sub>–L<sub>IV</sub>, FN and TH, respectively), CRP (β=-0.18, 0.23 and -0.22 for L<sub>I</sub>–L<sub>IV</sub>, FN and TH, respectively) and leptin (β=0.35, 0.32 and 0.42 for L<sub>I</sub>–L<sub>IV</sub>, FN and TH, respectively) were shown a significant association with BMD in all sites of measurement. It was independent of age, body mass index and postmenopause duration. Associations were also found between adiponectin and BMD of L<sub>I</sub>–L<sub>IV</sub> and TH (β=-0.36 and -0.28, respectively), CCPA and BMD of FN and TH (β=-0.21, -0.24, respectively) and IL-6 and BMD of FN (β=0.37).</p> <p><bold>Conclusion</bold><bold>. </bold>The study of biochemical and immunological markers in women with RA demonstrated that CRP, CCPA, PTH, IL-6, adiponectin, and leptin influenced BMD.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель. </bold>Изучить связь минеральной плотности кости (МПК) с биохимическими и иммунологическими маркерами сыворотки крови у женщин в постменопаузе с ревматоидным артритом (РА).</p> <p><bold>Материалы и методы. </bold>Обследованы 173 женщины с РА (возраст 61,0 [56,0; 66,0] года). Проведены опрос, двуэнергетическая рентгеновская абсорбциометрия для определения МПК поясничного отдела позвоночника (L<sub>I</sub>–L<sub>IV</sub>), шейки бедра (ШБ) и проксимального отдела бедра (ПОБ), рутинный биохимический анализ крови, определение С-реактивного белка (СРБ), ревматоидного фактора, антител к циклическому цитруллинированному пептиду (АЦЦП), паратиреоидного гормона (ПТГ), витамина D<sub>3</sub>, миостатина, фоллистатина, интерлейкина-6 (ИЛ-6), рецепторов к ИЛ-6, инсулиноподобного фактора роста 1, адипонектина, лептина, фактора роста фибробластов 23, фактора некроза опухоли SF12.</p> <p><bold>Результаты. </bold>Из 23 изученных гуморальных факторов независимую от возраста, индекса массы тела и длительности постменопаузы связь с МПК всех отделов продемонстрировали ПТГ (β=-0,22, -0,35 и -0,30 для L<sub>I</sub>–L<sub>IV</sub>, ШБ и ПОБ соответственно), СРБ (β=-0,18, -0,23 и -0,22 для L<sub>I</sub>–L<sub>IV</sub>, ШБ и ПОБ соответственно) и лептин (β=0,35, 0,32 и 0,42 для L<sub>I</sub>–L<sub>IV</sub>, ШБ и ПОБ соответственно). Выявлены также ассоциации между адипонектином и МПК L<sub>I</sub>–L<sub>IV</sub> и ПОБ (β=-0,36 и -0,28 соответственно), АЦЦП и МПК ШБ и ПОБ (β=-0,21, -0,24 соответственно) и ИЛ-6 и МПК ШБ (β=0,37).</p> <p><bold>Заключение. </bold>Таким образом, проведенное исследование биохимических и иммунологических маркеров у женщин с РА продемонстрировало, что на МПК оказывали влияние СРБ, АЦЦП, ПТГ, ИЛ-6, адипонектин и лептин.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>bone mineral density</kwd><kwd>osteoporosis</kwd><kwd>parathyroid hormone</kwd><kwd>cytokines</kwd><kwd>interleukin-6</kwd><kwd>adiponectin</kwd><kwd>leptin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>минеральная плотность кости</kwd><kwd>остеопороз</kwd><kwd>паратиреоидный гормон</kwd><kwd>цитокины</kwd><kwd>интерлейкин-6</kwd><kwd>адипонектин</kwd><kwd>лептин</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was supported by the Government. State Assignment No. 1021051403074-2 "Development of an interdisciplinary personalized model of care for patients with autoinflammatory degenerative diseases (osteoarthritis, osteoporosis, sarcopenia, gout, pyrophosphate arthropathy) and multimorbidity (obesity, cardiovascular diseases)"</funding-statement><funding-statement xml:lang="ru">Исследование было поддержано правительством. Госзадание №1021051403074-2 «Разработка междисциплинарной персонализированной модели оказания помощи пациентам с аутовоспалительными дегенеративными заболеваниями (остеоартрит, остеопороз, саркопения, подагра, пирофосфатная артропатия) и мультиморбидностью (ожирение, сердечно-сосудистые заболевания)»</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Premaor MO, Pilbrow L, Tonkin C, et al. Obesity and fractures in postmenopausal women. J Bone Miner Res. 2010;25(2):292-7. DOI:10.1359/jbmr.091004</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Crowson CS, Matteson EL, Davis JM 3rd, Gabriel SE. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(1):71-7. DOI:10.1002/acr.21660</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ko DS, Kim YH, Goh TS, Lee JS. Altered physiology of mesenchymal stem cells in the pathogenesis of adolescent idiopathic scoliosis. World J Clin Cases. 2020;8(11):2102-10. DOI:10.12998/wjcc.v8.i11.2102</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Aguirre L, Napoli N, Waters D, et al. Increasing adiposity is associated with higher adipokine levels and lower bone mineral density in obese older adults. J Clin Endocrinol Metab. 2014;99(9):3290-7. DOI:10.1210/jc.2013-3200</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lee S, Kim JH, Jeon YK, et al. Effect of adipokine and ghrelin levels on BMD and fracture risk: an updated systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1044039. DOI:10.3389/fendo.2023.1044039</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mangion D, Pace NP, Formosa MM. The relationship between adipokine levels and bone mass – A systematic review. Endocrinol Diabetes Metab. 2023;6(3):e408. DOI:10.1002/edm2.408</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Dankbar B, Fennen M, Brunert D, et al. Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat Med. 2015;21(9):1085-90. DOI:10.1038/nm.3917</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Solomon DH, Finkelstein JS, Shadick N, et al. The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1624-31. DOI:10.1002/art.24551</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Van der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int. 2013;24(4):1429-36. DOI:10.1007/s00198-012-2073-z</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hauser B, Harre U. The role of autoantibodies in bone metabolism and bone loss. Calcif Tissue Int. 2018;102(5):522-32. DOI:10.1007/s00223-017-0370-4</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Nagayama Y, Ebina K, Tsuboi H, et al. Low serum albumin concentration is associated with increased risk of osteoporosis in postmenopausal patients with rheumatoid arthritis. J Orthop Sci. 2022;27(6):1283-90. DOI:10.1016/j.jos.2021.08.018</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ketabforoush AHME, Aleahmad M, Qorbani M, et al. Bone mineral density status in patients with recent-onset rheumatoid arthritis. J Diabetes Metab Disord. 2023;22(1):775-85. DOI:10.1007/s40200-023-01200-w</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Moritani Y, Hasegawa T, Yamamoto T, et al. Histochemical assessment of accelerated bone remodeling and reduced mineralization in Il-6 deficient mice. J Oral Biosci. 2022;64(4):410-21. DOI:10.1016/j.job.2022.10.001</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Huang Z, Xu Z, Wan R, et al. Associations between blood inflammatory markers and bone mineral density and strength in the femoral neck: findings from the MIDUS II study. Sci Rep. 2023;13(1):10662. DOI:10.1038/s41598-023-37377-6</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Qiu J, Lu C, Zhang L, et al. Osteoporosis in patients with rheumatoid arthritis is associated with serum immune regulatory cellular factors. Clin Rheumatol. 2022;41(9):2685-93. DOI:10.1007/s10067-022-06212-0</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kota S, Jammula S, Kota S, et al. Correlation of vitamin D, bone mineral density and parathyroid hormone levels in adults with low bone density. Indian J Orthop. 2013;47(4):402-7. DOI:10.4103/0019-5413.114932</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Tan LM, Long TT, Guan XL, et al. Diagnostic value of vitamin D status and bone turnover markers in rheumatoid arthritis complicated by osteoporosis. Ann Clin Lab Sci. 2018;48(2):197-204. PMID: 29678847</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lee S, Kim JH, Jeon YK, et al. Effect of adipokine and ghrelin levels on BMD and fracture risk: an updated systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1044039. DOI:10.3389/fendo.2023.1044039</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Угай Л.Г., Невзорова В.А., Кочеткова Е.А., и др. Состояние адипокиновой регуляции и эндотелиальной дисфункции у пациентов с хронической обструктивной болезнью легких c различной минеральной плотностью костной ткани. Пульмонология. 2015;25(5):517-23 [Ugay LG, Nevzorova VA, Kochetkova EA, et al. Аdipokine regulation and endothelial dysfunction in patients with chronic obstructive pulmonary disease and different bone mineral density. Pulmonologiya. 2015;25(5):517-23 (in Russian)]. DOI:10.18093/0869-0189-2015-25-5-517-523</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Птичкина П.А., Скрипникова И.А., Новиков В.Е., и др. Композитный состав тела, костная масса и адипокины у женщин в постменопаузе с разным кардиоваскулярным риском (SCORE). Остеопороз и остеопатии. 2012;15(1):3-6 [Ptichkina PA, Skripnikova IA, Novikov VE, et al. Body composition, bone mass and adipokines in postmenopausal women with different cardiovascular risk (SCORE). Osteoporosis and Bone Diseases. 2012;15(1):3-6 (in Russian)]. DOI:10.14341/osteo201213-6</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Gong X, Tang Y, Yu SS, et al. Elevated serum leptin may be associated with disease activity and secondary osteoporosis in Chinese patients with rheumatoid arthritis. Clin Rheumatol. 2023;42(12):3333-40. DOI:10.1007/s10067-023-06725-2</mixed-citation></ref></ref-list></back></article>
